samedan logo
 
 
spacer
home > ict > summer 2020 > speeding clinical trial processes through greater agility
PUBLICATIONS
International Clinical Trials

Speeding Clinical Trial Processes Through Greater Agility


Life science organisations, in common with other businesses, are looking urgently towards technology to help them become more agile. Traditional ‘transformational’ projects that take 12-24 months – or even more – are no longer practical as businesses are unlikely to see immediate benefits. In a regulatory context, this is often the case given that global compliance is a moving target. Requirements are continuously being updated and supplemented.

This makes it impractical to try to define all probable needs upfront, then lock down an IT project and go through all the rigorous sequential stages of designing, approving, developing, validating/testing, piloting, and rolling out. By the time that end point comes, there is a strong possibility that needs will have changed and new regulatory requirements will be coming through. This then necessitates a new round of modifications and additions – incurring more delay, cost, and frustration.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the Author


Romuald Braun is VP of Strategy for Life Sciences at Amplexor. He holds a Master’s degree in Drug Regulatory Affairs, an Engineer’s Diploma in Data Technology, and has spent the last 26 years working in compliance, document management, and content management related roles in this industry – in client-based as well as consulting and project management roles.

romuald.braun@amplexor.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate

The Phase 3 ENSEMBLE study (NCT04505722) of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enrol and vaccinate study participants. ENSEMBLE is proceeding to enrol up to 60,000 participants worldwide.1
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement